JP5331817B2 - 新規な非選択的ソマトスタチン類似体 - Google Patents

新規な非選択的ソマトスタチン類似体 Download PDF

Info

Publication number
JP5331817B2
JP5331817B2 JP2010535349A JP2010535349A JP5331817B2 JP 5331817 B2 JP5331817 B2 JP 5331817B2 JP 2010535349 A JP2010535349 A JP 2010535349A JP 2010535349 A JP2010535349 A JP 2010535349A JP 5331817 B2 JP5331817 B2 JP 5331817B2
Authority
JP
Japan
Prior art keywords
phe
compound according
group
tyr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010535349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505345A (ja
JP2011505345A5 (OSRAM
Inventor
ヴィタリー アンドレア
ピノーリ マッシモ
マスカーニ パオロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20072266 external-priority patent/ITMI20072266A1/it
Priority claimed from EP07425778A external-priority patent/EP2067786A1/en
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of JP2011505345A publication Critical patent/JP2011505345A/ja
Publication of JP2011505345A5 publication Critical patent/JP2011505345A5/ja
Application granted granted Critical
Publication of JP5331817B2 publication Critical patent/JP5331817B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2010535349A 2007-12-03 2008-11-24 新規な非選択的ソマトスタチン類似体 Active JP5331817B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI2007A002266 2007-12-03
ITMI20072266 ITMI20072266A1 (it) 2007-12-03 2007-12-03 Nuovi analoghi non selettivi di somatostatina
EP07425778.3 2007-12-07
EP07425778A EP2067786A1 (en) 2007-12-07 2007-12-07 Novel non selective analogs of somatostatin
PCT/EP2008/066081 WO2009071460A2 (en) 2007-12-03 2008-11-24 New non-selective somatostatin analogues

Publications (3)

Publication Number Publication Date
JP2011505345A JP2011505345A (ja) 2011-02-24
JP2011505345A5 JP2011505345A5 (OSRAM) 2011-08-04
JP5331817B2 true JP5331817B2 (ja) 2013-10-30

Family

ID=40667736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010535349A Active JP5331817B2 (ja) 2007-12-03 2008-11-24 新規な非選択的ソマトスタチン類似体

Country Status (15)

Country Link
US (1) US8937152B2 (OSRAM)
EP (1) EP2225271B1 (OSRAM)
JP (1) JP5331817B2 (OSRAM)
KR (1) KR101500528B1 (OSRAM)
CN (1) CN101883785B (OSRAM)
BR (1) BRPI0818978B8 (OSRAM)
CA (1) CA2702940C (OSRAM)
CY (1) CY1114490T1 (OSRAM)
DK (1) DK2225271T3 (OSRAM)
ES (1) ES2431573T3 (OSRAM)
HR (1) HRP20130948T1 (OSRAM)
PL (1) PL2225271T3 (OSRAM)
PT (1) PT2225271E (OSRAM)
SI (1) SI2225271T1 (OSRAM)
WO (1) WO2009071460A2 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
CN101883785B (zh) * 2007-12-03 2014-01-15 意大利法尔马科有限公司 新的非选择性生长抑素类似物
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
SG10201601327RA (en) * 2011-09-04 2016-03-30 Glytech Inc Glycosylated polypeptide and drug composition containing said polypeptide
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
AU2014280847B2 (en) * 2013-06-13 2019-07-04 Antisense Therapeutics Ltd Combination therapy
CN103467575B (zh) * 2013-08-22 2016-03-02 深圳翰宇药业股份有限公司 一种帕西瑞肽的制备方法
CN103641894B (zh) * 2013-12-06 2015-10-28 深圳翰宇药业股份有限公司 一种治疗库欣病的多肽药物的制备方法
CN106999541A (zh) 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
CN104447962B (zh) * 2014-12-29 2018-07-17 成都圣诺生物科技股份有限公司 一种合成帕瑞肽的方法
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
CN117122707A (zh) * 2018-09-25 2023-11-28 意大利国际先进加速器应用有限公司 联合疗法
GB201816637D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd Selective somatostatin receptor agonists
AU2022228766A1 (en) * 2021-03-04 2023-09-07 Starget Pharma Ltd. Conformational constrained somatostatin receptor 3 peptide ligands and their conjugates and uses thereof
IT202100032615A1 (it) 2021-12-24 2023-06-24 Italfarmaco Spa Uso di un agonista della somatostatina nel trattamento di tumori che esprimono SSTR3
CN119708199A (zh) * 2023-09-27 2025-03-28 钱杭江医药科技(嘉兴)有限公司 生长抑素肽类类似物、螯合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US6365380B2 (en) * 2000-02-23 2002-04-02 Pcbu Services, Inc. Method for stereoselectively inverting a chiral center of a chemical compound using an enzyme and a metal catalyst
WO2003077878A1 (en) * 2002-03-12 2003-09-25 The Procter & Gamble Company Cosmetic composition comprising double coated pigment
GB0206415D0 (en) 2002-03-19 2002-05-01 Glaxo Group Ltd Deracemisation of amines
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
GB0318682D0 (en) * 2003-08-08 2003-09-10 Novartis Ag Organic compounds
EP1522311A1 (fr) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
CA2546448A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Biomarkers for the efficacy of somatostatin analogue treatment
ITFI20040057A1 (it) * 2004-03-10 2004-06-10 Mauro Giuntini Analoghi della somatostatina
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
US7824663B2 (en) * 2005-03-10 2010-11-02 Kokyu Alcohol Kogyo Co., Ltd. Lip gloss composition
PL1787658T3 (pl) * 2005-11-10 2012-08-31 Italfarmaco Spa Formulacje o przedłużonym uwalnianiu analogów somatostatyny będących inhibitorami hormonu wzrostu
CN101883785B (zh) * 2007-12-03 2014-01-15 意大利法尔马科有限公司 新的非选择性生长抑素类似物

Also Published As

Publication number Publication date
PT2225271E (pt) 2013-09-27
CY1114490T1 (el) 2016-10-05
ES2431573T3 (es) 2013-11-27
BRPI0818978A2 (pt) 2016-05-03
CA2702940A1 (en) 2009-06-11
CN101883785B (zh) 2014-01-15
BRPI0818978B8 (pt) 2021-05-25
EP2225271B1 (en) 2013-07-31
JP2011505345A (ja) 2011-02-24
CN101883785A (zh) 2010-11-10
EP2225271A2 (en) 2010-09-08
US20100323964A1 (en) 2010-12-23
WO2009071460A3 (en) 2009-12-17
WO2009071460A2 (en) 2009-06-11
KR101500528B1 (ko) 2015-03-09
DK2225271T3 (da) 2013-10-07
BRPI0818978B1 (pt) 2019-09-10
CA2702940C (en) 2016-09-13
KR20100103464A (ko) 2010-09-27
PL2225271T3 (pl) 2013-12-31
US8937152B2 (en) 2015-01-20
HRP20130948T1 (hr) 2013-11-08
SI2225271T1 (sl) 2013-10-30

Similar Documents

Publication Publication Date Title
JP5331817B2 (ja) 新規な非選択的ソマトスタチン類似体
KR101169846B1 (ko) 시클릭 펩티드 ｃｘｃｒ４ 길항제
JP5254868B2 (ja) ソマトスタチン−ドーパミンキメラ類似体
US20070154392A1 (en) Treatment process using somatostatin analogues
CN1189166A (zh) 抑生长素肽
JP2004339237A (ja) 治療効果のあるペプチド誘導体
JP2002518339A (ja) コンフォメーション的に拘束された主鎖環化ソマトスタチン類似体
CN112585157A (zh) 用于结合整联蛋白αvβ3的肽配体
CZ20033122A3 (cs) Chimérické somatostatin@dopaminové analogy
JP5908184B2 (ja) ソマトスタチン−ドーパミンのキメラ類似体
AU2004251866B2 (en) Pharmaceutical composition comprising cyclic somatostatin analogues
US20080132453A1 (en) Neuromedin B and somatostatin receptor agonists
EP2067786A1 (en) Novel non selective analogs of somatostatin
ITMI20072266A1 (it) Nuovi analoghi non selettivi di somatostatina
CN1812997B (zh) 包含促生长素抑制素类似物的胃肠外药物组合物
EP4656654A1 (en) Somatostatin peptide analogue, chelate and use thereof
RS51950B (sr) Ciklični peptidi antagonisti cxcr4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130729

R150 Certificate of patent or registration of utility model

Ref document number: 5331817

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250